Unmet needs and future directions in hypertrophic cardiomyopathy.

[1]  M. Link,et al.  Vigorous Exercise in Patients with Hypertrophic Cardiomyopathy: Results of the Prospective, Observational, Multinational, “Lifestyle and Exercise in HCM” (LIVE-HCM) Study , 2023, JAMA cardiology.

[2]  Gregory A. Newby,et al.  Efficient in vivo genome editing prevents hypertrophic cardiomyopathy in mice , 2023, Nature Medicine.

[3]  N. Smedira,et al.  Survival After Septal Reduction in Patients >65 Years Old With Obstructive Hypertrophic Cardiomyopathy. , 2023, Journal of the American College of Cardiology.

[4]  C. Kramer,et al.  Phase 2 Study of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy. , 2023, Journal of the American College of Cardiology.

[5]  D. Herzka,et al.  Reshaping the Ventricle From Within , 2022, JACC. Basic to translational science.

[6]  N. Smedira,et al.  Myosin Inhibition and Left Ventricular Diastolic Function in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy: Insights From the VALOR-HCM Study , 2022, Circulation. Cardiovascular imaging.

[7]  Matthew W. Martinez,et al.  Temporal and Global Trends of the Incidence of Sudden Cardiac Death in Hypertrophic Cardiomyopathy. , 2022, JACC. Clinical electrophysiology.

[8]  N. Smedira,et al.  Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy. , 2022, Journal of the American College of Cardiology.

[9]  R. Lederman,et al.  Transcatheter Myotomy to Treat Hypertrophic Cardiomyopathy and Enable Transcatheter Mitral Valve Replacement: First-in-Human Report of Septal Scoring Along the Midline Endocardium. , 2022, Circulation. Cardiovascular interventions.

[10]  J. Spertus,et al.  Validation of the Kansas City Cardiomyopathy Questionnaire in Symptomatic Obstructive Hypertrophic Cardiomyopathy. , 2022, JACC. Heart failure.

[11]  Shengshou Hu,et al.  Survival Following Alcohol Septal Ablation or Septal Myectomy for Patients With Obstructive Hypertrophic Cardiomyopathy. , 2022, Journal of the American College of Cardiology.

[12]  D. Herzka,et al.  Transcatheter Myotomy to Relieve Left Ventricular Outflow Tract Obstruction: The Septal Scoring Along the Midline Endocardium Procedure in Animals , 2022, Circulation. Cardiovascular interventions.

[13]  N. Smedira,et al.  Association of Septal Myectomy With Quality of Life in Patients With Left Ventricular Outflow Tract Obstruction From Hypertrophic Cardiomyopathy , 2022, JAMA network open.

[14]  Lei Zhang,et al.  Percutaneous Intramyocardial Septal Radiofrequency Ablation in Patients With Drug-Refractory Hypertrophic Obstructive Cardiomyopathy. , 2022, JAMA cardiology.

[15]  D. Fotiadis,et al.  Disease Progression of Hypertrophic Cardiomyopathy: Modeling Using Machine Learning , 2022, JMIR medical informatics.

[16]  E. Chin,et al.  Discovery of Aficamten (CK-274), a Next-Generation Cardiac Myosin Inhibitor for the Treatment of Hypertrophic Cardiomyopathy. , 2021, Journal of medicinal chemistry.

[17]  E. Ashley,et al.  Worldwide differences in primary prevention implantable cardioverter defibrillator utilization and outcomes in hypertrophic cardiomyopathy. , 2021, European heart journal.

[18]  C. Chiang,et al.  From Genetic Mutations to Molecular Basis of Heart Failure Treatment: An Overview of the Mechanism and Implication of the Novel Modulators for Cardiac Myosin , 2021, International journal of molecular sciences.

[19]  G. Pontone,et al.  Diagnosis and risk stratification in hypertrophic cardiomyopathy using machine learning wall thickness measurement: a comparison with human test-retest performance. , 2020, The Lancet. Digital health.

[20]  Howard K. Song,et al.  Thirty Controversies and Considerations in Hypertrophic Cardiomyopathy , 2020 .

[21]  Matthew W. Martinez,et al.  2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. , 2020, Circulation.

[22]  S. Solomon,et al.  Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial , 2020, The Lancet.

[23]  B. Maron,et al.  Outcomes in Patients With Hypertrophic Cardiomyopathy and Left Ventricular Systolic Dysfunction. , 2020, Journal of the American College of Cardiology.

[24]  E. Ashley,et al.  Silencing of MYH7 ameliorates disease phenotypes in human iPSC-Cardiomyocytes. , 2020, Physiological genomics.

[25]  S. Solomon,et al.  Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy. , 2020, Journal of the American College of Cardiology.

[26]  S. Colan,et al.  A Validated Model for Sudden Cardiac Death Risk Prediction in Pediatric Hypertrophic Cardiomyopathy , 2020, Circulation.

[27]  Michael J Ackerman,et al.  Detection of Hypertrophic Cardiomyopathy Using a Convolutional Neural Network-Enabled Electrocardiogram. , 2020, Journal of the American College of Cardiology.

[28]  J. F. Staples,et al.  Myosin Sequestration Regulates Sarcomere Function, Cardiomyocyte Energetics, and Metabolism, Informing the Pathogenesis of Hypertrophic Cardiomyopathy , 2020, Circulation.

[29]  P. Elliott,et al.  Prevalence and clinical significance of red flags in patients with hypertrophic cardiomyopathy. , 2020, International journal of cardiology.

[30]  S. Ommen,et al.  Survival Following Myectomy for Obstructive Hypertrophic Cardiomyopathy-What Causes Late Mortality? , 2019, The Annals of thoracic surgery.

[31]  M. Lafreniere-Roula,et al.  Family screening for hypertrophic cardiomyopathy: Is it time to change practice guidelines? , 2019, European heart journal.

[32]  N. Smedira,et al.  Surgical management of left ventricular outflow tract obstruction in a specialized hypertrophic obstructive cardiomyopathy center. , 2019, The Journal of thoracic and cardiovascular surgery.

[33]  Onur Dur,et al.  Machine learning detection of obstructive hypertrophic cardiomyopathy using a wearable biosensor , 2019, npj Digital Medicine.

[34]  A. Owens,et al.  Mavacamten Treatment for Obstructive Hypertrophic Cardiomyopathy , 2019, Annals of Internal Medicine.

[35]  K. Yeo,et al.  Killing two birds with one stone—MitraClip for flail P2 and systolic anterior motion of mitral valve: a case report , 2018, European heart journal. Case reports.

[36]  M. Barbarawi,et al.  Alcohol septal ablation vs myectomy for symptomatic hypertrophic obstructive cardiomyopathy: Systematic review and meta‐analysis , 2018, Clinical cardiology.

[37]  S. Markova,et al.  In vitro and in vivo pharmacokinetic characterization of mavacamten, a first-in-class small molecule allosteric modulator of beta cardiac myosin , 2018, Xenobiotica; the fate of foreign compounds in biological systems.

[38]  E. Ashley,et al.  Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy , 2018, Circulation.

[39]  M. Link,et al.  Exercise Training for Patients With Hypertrophic Cardiomyopathy: JACC Review Topic of the Week. , 2018, Journal of the American College of Cardiology.

[40]  N. Smedira,et al.  CONGENITAL : HYPERTROPHIC CARDIOMYOPATHY Prediction of sudden death risk in obstructive hypertrophic cardiomyopathy : Potential for refinement of current criteria , 2018 .

[41]  L. Carrier,et al.  Gene therapy strategies in the treatment of hypertrophic cardiomyopathy , 2018, Pflügers Archiv - European Journal of Physiology.

[42]  A. Keren,et al.  International External Validation Study of the 2014 European Society of Cardiology Guidelines on Sudden Cardiac Death Prevention in Hypertrophic Cardiomyopathy (EVIDENCE-HCM) , 2017, Circulation.

[43]  Yonghong Song,et al.  A small-molecule modulator of cardiac myosin acts on multiple stages of the myosin chemomechanical cycle , 2017, The Journal of Biological Chemistry.

[44]  Jianhui Gong,et al.  Correction of a pathogenic gene mutation in human embryos , 2017, Nature.

[45]  J. Spudich,et al.  Hypertrophic cardiomyopathy and the myosin mesa: viewing an old disease in a new light , 2017, Biophysical Reviews.

[46]  E. Ashley,et al.  Effect of Moderate-Intensity Exercise Training on Peak Oxygen Consumption in Patients With Hypertrophic Cardiomyopathy: A Randomized Clinical Trial , 2017, JAMA.

[47]  R. Swaminathan,et al.  Hospital Volume Outcomes After Septal Myectomy and Alcohol Septal Ablation for Treatment of Obstructive Hypertrophic Cardiomyopathy: US Nationwide Inpatient Database, 2003-2011. , 2016, JAMA cardiology.

[48]  M. Maron,et al.  Occurrence of Clinically Diagnosed Hypertrophic Cardiomyopathy in the United States. , 2016, The American journal of cardiology.

[49]  A. Oto,et al.  Glue septal ablation: A promising alternative to alcohol septal ablation , 2016, JRSM cardiovascular disease.

[50]  Barry J Maron,et al.  New perspectives on the prevalence of hypertrophic cardiomyopathy. , 2015, Journal of the American College of Cardiology.

[51]  C. Grines,et al.  Results of ventricular septal myectomy and hypertrophic cardiomyopathy (from Nationwide Inpatient Sample [1998-2010]). , 2014, The American journal of cardiology.

[52]  J. Veselka,et al.  Long-term survival after alcohol septal ablation for hypertrophic obstructive cardiomyopathy: a comparison with general population. , 2014, European heart journal.

[53]  E. Lander,et al.  Development and Applications of CRISPR-Cas9 for Genome Engineering , 2014, Cell.

[54]  Christine E. Seidman,et al.  Allele-Specific Silencing of Mutant Myh6 Transcripts in Mice Suppresses Hypertrophic Cardiomyopathy , 2013, Science.

[55]  N. Smedira,et al.  Predictors of Long-Term Outcomes in Symptomatic Hypertrophic Obstructive Cardiomyopathy Patients Undergoing Surgical Relief of Left Ventricular Outflow Tract Obstruction , 2013, Circulation.

[56]  S. Ommen,et al.  B-type natriuretic peptide and survival in hypertrophic cardiomyopathy. , 2013, Journal of the American College of Cardiology.

[57]  L. Køber,et al.  Penetrance of Hypertrophic Cardiomyopathy in Children and Adolescents: A 12-Year Follow-up Study of Clinical Screening and Predictive Genetic Testing , 2013, Circulation.

[58]  B. Gersh,et al.  Survival After Alcohol Septal Ablation for Obstructive Hypertrophic Cardiomyopathy , 2012, Circulation.

[59]  W. Williams,et al.  Long-term survival in patients with resting obstructive hypertrophic cardiomyopathy comparison of conservative versus invasive treatment. , 2011, Journal of the American College of Cardiology.

[60]  E. Leifer,et al.  Long-Term Follow-Up of Children and Adolescents Diagnosed with Hypertrophic Cardiomyopathy: Risk Factors for Adverse Arrhythmic Events , 2011, Pediatric Cardiology.

[61]  N. Smedira,et al.  Updated meta-analysis of septal alcohol ablation versus myectomy for hypertrophic cardiomyopathy. , 2010, Journal of the American College of Cardiology.

[62]  Deborah H. Kwon,et al.  Long-term outcomes in high-risk symptomatic patients with hypertrophic cardiomyopathy undergoing alcohol septal ablation. , 2008, JACC. Cardiovascular interventions.

[63]  L. Trinquart,et al.  Non-surgical septal myocardial reduction by coil embolization for hypertrophic obstructive cardiomyopathy: early and 6 months follow-up. , 2008, European heart journal.

[64]  A. Tajik,et al.  Surgical septal myectomy decreases the risk for appropriate implantable cardioverter defibrillator discharge in obstructive hypertrophic cardiomyopathy. , 2007, European heart journal.

[65]  A. Tajik,et al.  Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. , 2005, Journal of the American College of Cardiology.

[66]  W. Williams,et al.  Clinical and Echocardiographic Determinants of Long-Term Survival After Surgical Myectomy in Obstructive Hypertrophic Cardiomyopathy , 2005, Circulation.

[67]  E. Braunwald,et al.  Editorial: Hypertrophic Subaortic Stenosis—A Broadened Concept , 1962, Circulation.

[68]  E. Ashley,et al.  Association of Obesity With Adverse Long-term Outcomes in Hypertrophic Cardiomyopathy. , 2020, JAMA cardiology.

[69]  S. Naidu.  Performance Volume Thresholds for Alcohol Septal Ablation in Treating Hypertrophic Cardiomyopathy: Guidelines, Competency Statements, and Now Data. , 2018, The Canadian journal of cardiology.

[70]  H. Bundgaard,et al.  Effect of Institutional Experience on Outcomes of Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy. , 2018, The Canadian journal of cardiology.